Microbial colonization and lung function in adolescents with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 15, Issue 3, 2016, Pages 340-349

  Hector, Andreas ^a   Kirn, Tobias ^a   Ralhan, Anjali ^a   Graepler Mainka, Ute ^a   Berenbrinker, Sina ^a   Riethmueller, Joachim ^a   Hogardt, Michael ^b   Wagner, Marlies ^c   Pfleger, Andreas ^c   Autenrieth, Ingo ^a,d   Kappler, Matthias ^e   Griese, Matthias ^e   Eber, Ernst ^c   Martus, Peter ^a   Hartl, Dominik ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d German Center for Research in Infectious Disease (DZIF)   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bacteria; Colonization; Cystic fibrosis; Fungi; Infection; Lung

Indexed keywords

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL COLONIZATION; COHORT ANALYSIS; CYSTIC FIBROSIS; FEMALE; FOLLOW UP; FUNGAL COLONIZATION; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION RISK; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; AUSTRIA; GERMANY; ISOLATION AND PURIFICATION; LUNG; LUNG ASPERGILLOSIS; LUNG FUNCTION TEST; MICROBIOLOGY; ORGANISMAL INTERACTION; PATHOPHYSIOLOGY; PROCEDURES; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; STATISTICS;

ADOLESCENT; ASPERGILLUS FUMIGATUS; AUSTRIA; CYSTIC FIBROSIS; FEMALE; GERMANY; HUMANS; LUNG; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL INTERACTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PULMONARY ASPERGILLOSIS; RESPIRATORY FUNCTION TESTS; STAPHYLOCOCCAL INFECTIONS; STATISTICS AS TOPIC;

EID: 84969651086     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.01.004     Document Type: Article

References (57)

1. Stoltz D.A., Meyerholz D.K., Welsh M.J. Origins of cystic fibrosis lung disease. N Engl J Med 2015, 372:351-362.
2. Ratjen F.A. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009, 54:595-605.
3. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
4. Ramsey K.A., Ranganathan S., Park J., Skoric B., Adams A.M., Simpson S.J., et al. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med 2014, 190:1111-1116.
5. Mayer-Hamblett N., Rosenfeld M., Gibson R.L., Ramsey B.W., Kulasekara H.D., Retsch-Bogart G.Z., et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 2014, 190:289-297.
6. Doring G., Flume P., Heijerman H., Elborn J.S., Consensus S.G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012, 11:461-479.
7. Sagel S.D., Gibson R.L., Emerson J., McNamara S., Burns J.L., Wagener J.S., et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009, 154:183-188.
8. Bendiak G.N., Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 2009, 30:587-595.
9. Chmiel J.F., Aksamit T.R., Chotirmall S.H., Dasenbrook E.C., Elborn J.S., LiPuma J.J., et al. Antibiotic management of lung infections in cystic fibrosis. I. the microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014, 11:1120-1129.
10. Chmiel J.F., Aksamit T.R., Chotirmall S.H., Dasenbrook E.C., Elborn J.S., LiPuma J.J., et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc 2014, 11:1298-1306.
11. Waters V. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des 2012, 18:696-725.
12. de Vrankrijker A.M., Wolfs T.F., van der Ent C.K. Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010, 11:246-254.
13. Muhlebach M.S., Heltshe S.L., EB P., MB M., Thompson V., Kloster M., et al. Multicenter observational study on factors and outcomes associated with different MRSA types in children with cystic fibrosis. Ann Am Thorac Soc 2015.
14. Lo D.K., Hurley M.N., Muhlebach M.S., Smyth A.R. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2015, 2.
15. Wolter D.J., Emerson J.C., McNamara S., Buccat A.M., Qin X., Cochrane E., et al. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis 2013, 57:384-391.
16. Goss C.H., Muhlebach M.S. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011, 10:298-306.
17. Dasenbrook E.C. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr Opin Pulm Med 2011, 17:437-441.
18. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303:2386-2392.
19. Dasenbrook E.C., Merlo C.A., Diener-West M., Lechtzin N., Boyle M.P. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
20. Adjemian J., Olivier K.N., Prevots D.R. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014, 190:581-586.
21. Leung J.M., Olivier K.N. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 2013, 19:662-669.
22. Nick J.A. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med 2003, 24:693-702.
23. Griffith D.E. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:810-812.
24. Olivier K.N., Weber D.J., Wallace R.J., Faiz A.R., Lee J.H., Zhang Y., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
25. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955-959.
26. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183:635-640.
27. Waters V., Atenafu E.G., Salazar J.G., Lu A., Yau Y., Matukas L., et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012, 11:8-13.
28. Waters V., Atenafu E.G., Lu A., Yau Y., Tullis E., Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013, 12:482-486.
29. Stanojevic S., Ratjen F., Stephens D., Lu A., Yau Y., Tullis E., et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013, 12:575-583.
30. Sherrard L.J., Tunney M.M., Elborn J.S. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014, 384:703-713.
31. Atemwegsinfecktionen bei Mukoviszidose. Mikrobiologisch-infektiologische Qualitätsstandards MiQ Qualitätssicherungskommission der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). 2006;24.
32. Hogardt M., Ulrich J., Riehn-Kopp H., Tummler B. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J Clin Microbiol 2009, 47:3435-3438.
33. Balke B., Schmoldt S., Haussler S., Suerbaum S., Heesemann J., Hogardt M. A German external quality survey of diagnostic microbiology of respiratory tract infections in patients with cystic fibrosis. J Cyst Fibros 2008, 7:7-14.
34. Standardization of Spirometry - 1994 Update. Am J Respir Crit Care Med. (1995);152:1107-1136.
35. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
36. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
37. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
38. Vandenbranden S.L., McMullen A., Schechter M.S., Pasta D.J., Michaelis R.L., Konstan M.W., et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012, 47:135-143.
39. Registry C.F.F.P. Annual Data Report to the Center Directors, Bethesda, MD 2013, Cystic Fibrosis Foundation.
40. Wong J.K., Ranganathan S.C. Hart E, Australian respiratory early surveillance team for cystic F. Staphylococcus aureus in early cystic fibrosis lung disease. Pediatr Pulmonol 2013, 48:1151-1159.
41. Chotirmall S.H., Greene C.M., NG M.E. Candida Species in cystic fibrosis: a road less travelled. Med Mycol 2010, 48:S114-S124.
42. Chotirmall S.H., O'Donoghue E., Bennett K., Gunaratnam C., O'Neill S.J., McElvaney N.G. Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest 2010, 138:1186-1195.
43. Brunke S., Hube B. Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell Microbiol 2013, 15:701-708.
44. Coughlan C.A., Chotirmall S.H., Renwick J., Hassan T., Low T.B., Bergsson G., et al. The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med 2012, 186:999-1007.
45. Amin R., Dupuis A., Aaron S.D., Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010, 137:171-176.
46. Aaron S.D., Vandemheen K.L., Freitag A., Pedder L., Cameron W., Lavoie A., et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012, 7.
47. McMahon M.A., Chotirmall S.H., McCullagh B., Branagan P., McElvaney N.G., Logan P.M. Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis population. Eur J Radiol 2012, 81:e197-e202.
48. Jones A.M., Horsley A., Denning D.W. What is the importance of classifying Aspergillus disease in cystic fibrosis patients?. Expert Rev Respir Med 2014, 1-4.
49. Baxter C.G., Dunn G., Jones A.M., Webb K., Gore R., Richardson M.D., et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013, 132:560-566. e10.
50. Chotirmall S.H., McElvaney N.G. Fungi in the cystic fibrosis lung: bystanders or pathogens?. Int J Biochem Cell Biol 2014, 52:161-173.
51. Baxter C.G., Rautemaa R., Jones A.M., Webb A.K., Bull M., Mahenthiralingam E., et al. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Thorax 2013, 68:652-657.
52. Moss R.B. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010, 16:598-603.
53. Surette M.G. The cystic fibrosis lung microbiome. Ann Am Thorac Soc 2014, 11(Suppl. 1):S61-S65.
54. Lynch S.V., Bruce K.D. The cystic fibrosis airway microbiome. Cold Spring Harb Perspect Med 2013, 3:a009738.
55. Proesmans M., Balinska-Miskiewicz W., Dupont L., Bossuyt X., Verhaegen J., Hoiby N., et al. Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 2006, 27:937-943.
56. Qvist T, Taylor-Robinson D, Waldmann E, Olesen HV, Hansen CR, Mathiesen IH, et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2015.
57. Qvist T., Gilljam M., Jonsson B., Taylor-Robinson D., Jensen-Fangel S., Wang M., et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 2015, 14:46-52.